EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma

Yoon Duk Hong iD, Lindsey Enewold, Elad Sharon, Jeremy L Warner, Amy J Davidoff iD, Chris Zeruto, Angela B Mariotto

Cancer Medicine · 2024-08 · 13 (16)

DOI: 10.1002/cam4.70131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.08.2024. Verfasst von Yoon Duk Hong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, SEER Program, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In the last decade, melanoma treatment has improved significantly. However, data on population‐level treatment utilization and survival trends among older patients is limited. This study aimed to analyze trends in systemic anticancer therapy (Rx), including the uptake of immune checkpoint inhibitors (ICIs), in conjunction with trends in cause‐specific survival among older patients (66+) diagnosed with advanced melanoma (2008–2019).

Methods

We used the Surveillance, Epidemiology, and End Results (SEER)‐Medicare Condensed Resource to assess any Rx utilization among patients first diagnosed with advanced melanoma in 2008–2010, 2011–2014, and 2015–2019, stratified by stage, and type of first‐line Rx among patients receiving Rx. The SEER dataset was used to evaluate trends in cause‐specific survival by year of diagnosis.

Results

Rx utilization (any type) almost doubled, from 28.6% (2008–2010) to 55.4% (2015–2019) for stage 3 melanoma, and from 35.5% to 68.0% for stage 4 melanoma. In 2008–2010, the standard first‐line treatment was cytokines/cytotoxic chemotherapy/other. By 2015–2019, only 5.1% (stage 3) and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsSEER ProgramImmune Checkpoint InhibitorsNeoplasm StagingHumansAgedMaleFemaleAged, 80 and overUnited StatesCutaneous Malignant MelanomaMedicareAntineoplastic Agents

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
  • Kelly Services, Inc., Rockville, Maryland, USA.
  • Division of Cancer Treatment & Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
  • Lifespan Cancer Institute, Rhode Island Hospital, Providence, Rhode Island, USA.
  • Center for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center, Brown University, Providence, Rhode Island, USA.
  • Information Management Services, Inc., Calverton, Maryland, USA.

ORCID-Profile: Yoon Duk Hong, Amy J Davidoff

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hong, Y. D., Enewold, L., Sharon, E., Warner, J. L., Davidoff, A. J., Zeruto, C., & Mariotto, A. B. (2024). Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma. Cancer Medicine, 13(16). https://doi.org/10.1002/cam4.70131

Vancouver

Hong YD, Enewold L, Sharon E, Warner JL, Davidoff AJ, Zeruto C, et al. Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma. Cancer Medicine. 2024;13(16). doi:10.1002/cam4.70131

BibTeX
@article{Hong2024,
  author = {Hong, Yoon Duk and Enewold, Lindsey and Sharon, Elad and Warner, Jeremy L and Davidoff, Amy J and Zeruto, Chris and Mariotto, Angela B},
  title = {Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {16},
  doi = {10.1002/cam4.70131}
}
Kostenlos starten →